Sheikh Tamir Rashid
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sheikh Tamir Rashid has a total of 320 co-authors. Here are the top co-authors by number of shared publications:
Soon Seng Ng
Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
10 shared publications- David A. Lomas
UCL Respiratory, Division of Medicine, University College London, London, U.K.
6 shared publications Deniz Kent
Department of Metabolism, Digestion and Reproduction, Imperial College London, London, UK
6 shared publications- Ludovic Vallier
Max Planck Institute for Molecular Genetics, Berlin, Germany
6 shared publications Hiromitsu Nakauchi
Institute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA
5 shared publications- Stefan John Marciniak
Cambridge Institute for Medical Research University of Cambridge Cambridge UK
5 shared publications
Latest Publications
- Open Access
Precision Gene-Based Therapy for Progressive Familial Intrahepatic Cholestasis: Matching Platform to Disease Biology
Progressive familial intrahepatic cholestasis (PFIC) encompasses genetically heterogeneous disorders affecting bile transport, membrane organisation, epithelial polarity and bile-acid signalling. Current medical and surgical treatments can improve symptoms and disease course in selected patients, but substantial unmet need remains, particularly in severe early-onset disease and multisystem disorders. This review considers the thirteen numbered PFIC subtypes and selected related monogenic cholestatic conditions, relating their mechanisms to gene addition, genome editing, splice correction, messenger RNA replacement and cell-based strategies. Published PFIC intervention evidence is predominantly preclinical, with proof of concept in selected mouse models and in vitro systems. Clinical experience in other liver diseases provides relevant delivery and safety precedents but does not establish efficacy in PFIC. Platform selection will depend on molecular mechanism, target tissue, therapeutic threshold, disease stage and the durability required during liver growth. Severe disease identifies unmet need rather than a proven optimal platform. We propose a framework for research prioritisation and identify the studies needed to establish sustained benefit, genomic and immunological safety, and clinically meaningful outcomes.
Open AccessPrecision Gene-Based Therapy for Progressive Familial Intrahepatic Cholestasis: Matching Platform to Disease Biology
Progressive familial intrahepatic cholestasis (PFIC) encompasses genetically heterogeneous disorders affecting bile transport, membrane organisation, epithelial polarity and bile-acid signalling. Current medical and surgical treatments can improve symptoms and disease course in selected patients, but substantial unmet need remains, particularly in severe early-onset disease and multisystem disorders. This review considers the thirteen numbered PFIC subtypes and selected related monogenic cholestatic conditions, relating their mechanisms to gene addition, genome editing, splice correction, messenger RNA replacement and cell-based strategies. Published PFIC intervention evidence is predominantly preclinical, with proof of concept in selected mouse models and in vitro systems. Clinical experience in other liver diseases provides relevant delivery and safety precedents but does not establish efficacy in PFIC. Platform selection will depend on molecular mechanism, target tissue, therapeutic threshold, disease stage and the durability required during liver growth. Severe disease identifies unmet need rather than a proven optimal platform. We propose a framework for research prioritisation and identify the studies needed to establish sustained benefit, genomic and immunological safety, and clinically meaningful outcomes.
- Open Access
- 12 October 2026
- Published by MDPI AG in Preprints.org
Precision Gene-Based Therapy for PFIC: Matching Platform to Disease Biology
Progressive familial intrahepatic cholestasis (PFIC) encompasses genetically heterogeneous disorders affecting bile transport, membrane organisation, epithelial polarity and bile-acid signalling. Current medical and surgical treatments can improve symptoms and disease course in selected patients, but substantial unmet need remains, particularly in severe early-onset disease and multisystem disorders. This review considers the thirteen numbered PFIC subtypes and selected related monogenic cholestatic conditions, relating their mechanisms to gene addition, genome editing, splice correction, messenger RNA replacement and cell-based strategies. Published PFIC intervention evidence is predominantly preclinical, with proof of concept in selected mouse models and in vitro systems. Clinical experience in other liver diseases provides relevant delivery and safety precedents but does not establish efficacy in PFIC. Platform selection will depend on molecular mechanism, target tissue, therapeutic threshold, disease stage and the durability required during liver growth. Severe disease identifies unmet need rather than a proven optimal platform. We propose a framework for research prioritisation and identify the studies needed to establish sustained benefit, genomic and immunological safety, and clinically meaningful outcomes.
- 12 October 2026
- Published by MDPI AG in Preprints.org
Open AccessPrecision Gene-Based Therapy for PFIC: Matching Platform to Disease Biology
Progressive familial intrahepatic cholestasis (PFIC) encompasses genetically heterogeneous disorders affecting bile transport, membrane organisation, epithelial polarity and bile-acid signalling. Current medical and surgical treatments can improve symptoms and disease course in selected patients, but substantial unmet need remains, particularly in severe early-onset disease and multisystem disorders. This review considers the thirteen numbered PFIC subtypes and selected related monogenic cholestatic conditions, relating their mechanisms to gene addition, genome editing, splice correction, messenger RNA replacement and cell-based strategies. Published PFIC intervention evidence is predominantly preclinical, with proof of concept in selected mouse models and in vitro systems. Clinical experience in other liver diseases provides relevant delivery and safety precedents but does not establish efficacy in PFIC. Platform selection will depend on molecular mechanism, target tissue, therapeutic threshold, disease stage and the durability required during liver growth. Severe disease identifies unmet need rather than a proven optimal platform. We propose a framework for research prioritisation and identify the studies needed to establish sustained benefit, genomic and immunological safety, and clinically meaningful outcomes.
- Open Access
- 5 March 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (5) , 608-613
Prevalence of liver disease and liver transplantation in pediatric ZZ alpha-1 antitrypsin deficiency: A systematic review and meta-analysis
- 5 March 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (5) , 608-613
Open AccessPrevalence of liver disease and liver transplantation in pediatric ZZ alpha-1 antitrypsin deficiency: A systematic review and meta-analysis
- Open Access
- 11 April 2025
- Published by Wiley in Liver International Communications
- Vol. 6 (2) , e70013
Liver Disease and Prevalence of Liver Transplantation in Adults With ZZ Alpha‐1 Antitrypsin Deficiency—A Meta‐Analysis
Alpha‐1 antitrypsin deficiency (A1ATD) is an inherited metabolic disorder caused by a mutation (ZZ) in the SERPINA1 gene. Carriers are predisposed to liver and lung pathology. The severity of A1ATD‐associated liver disease is highly variable, necessitating further characterisation. This study aims to investigate the risk and extent of liver disease and the prevalence of liver transplantation in ZZ A1ATD patients. Several established databases, including Ovid, EBSCO, PubMed, and Cochrane Library, were searched from inception to May 12, 2024. Data were pooled using a random effects model, and study weight was calculated using the inverse variance method. Crude odds ratios (cOR) were calculated using participants with the MM genotype as the comparator. The study was registered in PROSPERO (CRD42022335666). Of the 4420 studies identified, 45 studies and 8638 A1ATD patients (38.8% female) were included. ZZ A1ATD patients demonstrate an increased risk of liver diseases compared to controls, including steatosis (crude odds ratio (cOR): 1.52 [95% CI: 1.21, 1.91]), fibrosis (cOR: 9.85 [95% CI: 5.70, 17.03]), cirrhosis (cOR: 10.43 [95% CI: 5.51, 19.73]), and liver cancers (cOR: 14.12 [95% CI: 6.50, 30.66]). The prevalence of liver transplantation is considerable, with rates reaching 5% [95% CI: 0.00, 12.34]. Our findings confirm the substantial burden of liver disease in ZZ A1ATD patients, including subclinical manifestations such as steatosis and fibrosis that may remain undetected. Given the lack of approved treatments for A1ATD‐associated liver disease, prioritising the development of novel therapies to stop or reverse liver disease is essential.
- 11 April 2025
- Published by Wiley in Liver International Communications
- Vol. 6 (2) , e70013
Open AccessLiver Disease and Prevalence of Liver Transplantation in Adults With ZZ Alpha‐1 Antitrypsin Deficiency—A Meta‐Analysis
Alpha‐1 antitrypsin deficiency (A1ATD) is an inherited metabolic disorder caused by a mutation (ZZ) in the SERPINA1 gene. Carriers are predisposed to liver and lung pathology. The severity of A1ATD‐associated liver disease is highly variable, necessitating further characterisation. This study aims to investigate the risk and extent of liver disease and the prevalence of liver transplantation in ZZ A1ATD patients. Several established databases, including Ovid, EBSCO, PubMed, and Cochrane Library, were searched from inception to May 12, 2024. Data were pooled using a random effects model, and study weight was calculated using the inverse variance method. Crude odds ratios (cOR) were calculated using participants with the MM genotype as the comparator. The study was registered in PROSPERO (CRD42022335666). Of the 4420 studies identified, 45 studies and 8638 A1ATD patients (38.8% female) were included. ZZ A1ATD patients demonstrate an increased risk of liver diseases compared to controls, including steatosis (crude odds ratio (cOR): 1.52 [95% CI: 1.21, 1.91]), fibrosis (cOR: 9.85 [95% CI: 5.70, 17.03]), cirrhosis (cOR: 10.43 [95% CI: 5.51, 19.73]), and liver cancers (cOR: 14.12 [95% CI: 6.50, 30.66]). The prevalence of liver transplantation is considerable, with rates reaching 5% [95% CI: 0.00, 12.34]. Our findings confirm the substantial burden of liver disease in ZZ A1ATD patients, including subclinical manifestations such as steatosis and fibrosis that may remain undetected. Given the lack of approved treatments for A1ATD‐associated liver disease, prioritising the development of novel therapies to stop or reverse liver disease is essential.
- 2 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (3) , 903-916
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors
Alpha-1 antitrypsin deficiency (A1ATD) is a life-threatening condition caused by inheritance of the SERPINA1 ‘Z’ genetic variant (PiZ) driving AAT protein misfolding in hepatocytes. There remain no approved medicines for this disease. Here, we report the results of a small molecule screen performed in patient derived iPSC-hepatocytes that identified Leucine-rich repeat kinase-2 (LRRK2) as a potentially new therapeutic target. Of the commercially available LRRK2 inhibitors tested, we identified CZC-25146, a candidate with favorable pharmacokinetic properties, as being capable of reducing polymer load, increasing normal AAT secretion, and reducing inflammatory cytokines in both cells and PiZ mice. Mechanistically, this effect was achieved through induction of autophagy. Our findings support the use of CZC-25146 and LRRK2 inhibitors in hepatic proteinopathy research and their further investigation as novel therapeutic candidates for A1ATD. Export
- 2 July 2024
- Published by Wolters Kluwer Health in Hepatology
- Vol. 81 (3) , 903-916
Reduction of Z alpha-1 antitrypsin polymers in human iPSC-hepatocytes and mice by LRRK2 inhibitors
Alpha-1 antitrypsin deficiency (A1ATD) is a life-threatening condition caused by inheritance of the SERPINA1 ‘Z’ genetic variant (PiZ) driving AAT protein misfolding in hepatocytes. There remain no approved medicines for this disease. Here, we report the results of a small molecule screen performed in patient derived iPSC-hepatocytes that identified Leucine-rich repeat kinase-2 (LRRK2) as a potentially new therapeutic target. Of the commercially available LRRK2 inhibitors tested, we identified CZC-25146, a candidate with favorable pharmacokinetic properties, as being capable of reducing polymer load, increasing normal AAT secretion, and reducing inflammatory cytokines in both cells and PiZ mice. Mechanistically, this effect was achieved through induction of autophagy. Our findings support the use of CZC-25146 and LRRK2 inhibitors in hepatic proteinopathy research and their further investigation as novel therapeutic candidates for A1ATD. Export
- Open Access
- 22 December 2022
- Published by Elsevier in Biomaterials
- Vol. 293, 121982
RGD density along with substrate stiffness regulate hPSC hepatocyte functionality through YAP signalling
- 22 December 2022
- Published by Elsevier in Biomaterials
- Vol. 293, 121982
Open AccessRGD density along with substrate stiffness regulate hPSC hepatocyte functionality through YAP signalling
- Open Access
- 19 December 2022
- Published by Springer Nature in Nature Metabolism
- Vol. 4 (12) , 1812-1829
Liver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice
RNA alternative splicing (AS) expands the regulatory potential of eukaryotic genomes. The mechanisms regulating liver-specific AS profiles and their contribution to liver function are poorly understood. Here, we identify a key role for the splicing factor RNA-binding Fox protein 2 (RBFOX2) in maintaining cholesterol homeostasis in a lipogenic environment in the liver. Using enhanced individual-nucleotide-resolution ultra-violet cross-linking and immunoprecipitation, we identify physiologically relevant targets of RBFOX2 in mouse liver, including the scavenger receptor class B type I (Scarb1). RBFOX2 function is decreased in the liver in diet-induced obesity, causing a Scarb1 isoform switch and alteration of hepatocyte lipid homeostasis. Our findings demonstrate that specific AS programmes actively maintain liver physiology, and underlie the lipotoxic effects of obesogenic diets when dysregulated. Splice-switching oligonucleotides targeting this network alleviate obesity-induced inflammation in the liver and promote an anti-atherogenic lipoprotein profile in the blood, underscoring the potential of isoform-specific RNA therapeutics for treating metabolism-associated diseases.
- 19 December 2022
- Published by Springer Nature in Nature Metabolism
- Vol. 4 (12) , 1812-1829
Open AccessLiver RBFOX2 regulates cholesterol homeostasis via Scarb1 alternative splicing in mice
RNA alternative splicing (AS) expands the regulatory potential of eukaryotic genomes. The mechanisms regulating liver-specific AS profiles and their contribution to liver function are poorly understood. Here, we identify a key role for the splicing factor RNA-binding Fox protein 2 (RBFOX2) in maintaining cholesterol homeostasis in a lipogenic environment in the liver. Using enhanced individual-nucleotide-resolution ultra-violet cross-linking and immunoprecipitation, we identify physiologically relevant targets of RBFOX2 in mouse liver, including the scavenger receptor class B type I (Scarb1). RBFOX2 function is decreased in the liver in diet-induced obesity, causing a Scarb1 isoform switch and alteration of hepatocyte lipid homeostasis. Our findings demonstrate that specific AS programmes actively maintain liver physiology, and underlie the lipotoxic effects of obesogenic diets when dysregulated. Splice-switching oligonucleotides targeting this network alleviate obesity-induced inflammation in the liver and promote an anti-atherogenic lipoprotein profile in the blood, underscoring the potential of isoform-specific RNA therapeutics for treating metabolism-associated diseases.
- Open Access
- 2 February 2022
- Published by Springer Nature in Research Square
Small molecule screen employing patient-derived iPSC hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency (A1ATD) is a life-threatening condition caused by inheritance of the SERPINA1-Z genetic variant (PiZ) leading to protein misfolding and liver toxicity. There remain no approved medicines for this disease. Here we report the results of a small molecule screen performed in patient-derived iPSC hepatocytes that identified Leucine-rich repeat kinase-2 (LRRK2), as a potentially new therapeutic target. Genetic deletion of LRRK2 in PiZ mice reduced both intrahepatic misfolded polymers and fibrosis leading us to test a library of commercially available LRRK2 inhibitors across several cell models. One of these molecules, CZC-25146, a candidate with favourable pharmacokinetic properties, reduced polymer load, increased normal AAT secretion and reduced inflammatory cytokines in both cells and the PiZ mouse. Mechanistically, this effect was achieved via inhibition of LRRK2 kinase activity and autophagy induction. These findings support the use of CZC-25146 (and potentially LRRK2 inhibitors more broadly) in hepatic proteinopathy disease research and as potential new therapies.
- 2 February 2022
- Published by Springer Nature in Research Square
Open AccessSmall molecule screen employing patient-derived iPSC hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency (A1ATD) is a life-threatening condition caused by inheritance of the SERPINA1-Z genetic variant (PiZ) leading to protein misfolding and liver toxicity. There remain no approved medicines for this disease. Here we report the results of a small molecule screen performed in patient-derived iPSC hepatocytes that identified Leucine-rich repeat kinase-2 (LRRK2), as a potentially new therapeutic target. Genetic deletion of LRRK2 in PiZ mice reduced both intrahepatic misfolded polymers and fibrosis leading us to test a library of commercially available LRRK2 inhibitors across several cell models. One of these molecules, CZC-25146, a candidate with favourable pharmacokinetic properties, reduced polymer load, increased normal AAT secretion and reduced inflammatory cytokines in both cells and the PiZ mouse. Mechanistically, this effect was achieved via inhibition of LRRK2 kinase activity and autophagy induction. These findings support the use of CZC-25146 (and potentially LRRK2 inhibitors more broadly) in hepatic proteinopathy disease research and as potential new therapies.
- Open Access
- 1 February 2022
- Published by Elsevier in JHEP Reports
- Vol. 4 (4) , 100446
Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
- 1 February 2022
- Published by Elsevier in JHEP Reports
- Vol. 4 (4) , 100446
Open AccessHuman iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency
- Open Access
Small molecule screen employing patient-derived iPS hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency is a life-threatening condition caused by inheritance of the SERPINA1 gene ‘Z’ variant. This single base pair mutation leads to protein misfolding, ER entrapment and gain of toxic function. Despite the significant unmet medical need presented by this disorder, there remain no approved medicines and the only curative option is liver transplantation. We hypothesized that an unbiased screen of human hepatocytes harbouring the Z mutation (ATZ) using small molecules targeted against protein degradation pathways would uncover novel biological insights of therapeutic relevance. Here we report the results of that screen performed in a patient-derived iPSC model of ATZ. Starting from 1,041 compounds we identified 14 targets capable of reducing polymer burden, including Leucine-rich repeat kinase-2 (LRRK2), a well-studied target in Parkinson’s. Genetic deletion of LRRK2 in ATZ mice reduced polymers and associated fibrotic liver disease leading us to test a library of commercially available LRRK2 kinase inhibitors in both patient iPSC and CHO cell models. One of the molecules tested, CZC-25146, reduced polymer load, increased normal AAT secretion and reduced inflammatory cytokines with pharmacokinetic properties supporting its potential use for treating liver diseases. We therefore tested CZC-25146 in the ATZ mouse model and confirmed its efficacy for polymer reduction without signs of toxicity. Mechanistically, in both human and mouse models, our data show CZC-25146 inhibits LRRK2 kinase activity and induces autophagy. Cumulatively, these findings support the use of CZC-25146 and LRRK2 inhibitors in general in hepatic proteopathy disease research and as potential new treatment approaches for patients. One Sentence Summary: A small molecule screen in patient iPSCs with in vivo validation in mice identifies LRRK2 as a new therapeutic target for Alpha-1 Antitrypsin Deficiency.
Open AccessSmall molecule screen employing patient-derived iPS hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency
Alpha-1 antitrypsin deficiency is a life-threatening condition caused by inheritance of the SERPINA1 gene ‘Z’ variant. This single base pair mutation leads to protein misfolding, ER entrapment and gain of toxic function. Despite the significant unmet medical need presented by this disorder, there remain no approved medicines and the only curative option is liver transplantation. We hypothesized that an unbiased screen of human hepatocytes harbouring the Z mutation (ATZ) using small molecules targeted against protein degradation pathways would uncover novel biological insights of therapeutic relevance. Here we report the results of that screen performed in a patient-derived iPSC model of ATZ. Starting from 1,041 compounds we identified 14 targets capable of reducing polymer burden, including Leucine-rich repeat kinase-2 (LRRK2), a well-studied target in Parkinson’s. Genetic deletion of LRRK2 in ATZ mice reduced polymers and associated fibrotic liver disease leading us to test a library of commercially available LRRK2 kinase inhibitors in both patient iPSC and CHO cell models. One of the molecules tested, CZC-25146, reduced polymer load, increased normal AAT secretion and reduced inflammatory cytokines with pharmacokinetic properties supporting its potential use for treating liver diseases. We therefore tested CZC-25146 in the ATZ mouse model and confirmed its efficacy for polymer reduction without signs of toxicity. Mechanistically, in both human and mouse models, our data show CZC-25146 inhibits LRRK2 kinase activity and induces autophagy. Cumulatively, these findings support the use of CZC-25146 and LRRK2 inhibitors in general in hepatic proteopathy disease research and as potential new treatment approaches for patients. One Sentence Summary: A small molecule screen in patient iPSCs with in vivo validation in mice identifies LRRK2 as a new therapeutic target for Alpha-1 Antitrypsin Deficiency.